https://stock.noler.com/us/stock/loxo-oncology-inc https://stock.noler.com/us/stock/loxo-oncology-inc/accounts-payable https://stock.noler.com/us/stock/loxo-oncology-inc/accrued-bonuses-current-and-noncurrent https://stock.noler.com/us/stock/loxo-oncology-inc/accrued-liabilities-current https://stock.noler.com/us/stock/loxo-oncology-inc/additional-paid-in-capital https://stock.noler.com/us/stock/loxo-oncology-inc/adjustment-for-amortization https://stock.noler.com/us/stock/loxo-oncology-inc/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/loxo-oncology-inc/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/loxo-oncology-inc/aoci https://stock.noler.com/us/stock/loxo-oncology-inc/available-for-sale-amortized-cost https://stock.noler.com/us/stock/loxo-oncology-inc/available-for-sale-debt-accumulated-gross-unrealized-loss-before-tax https://stock.noler.com/us/stock/loxo-oncology-inc/available-for-sale-debt-securities https://stock.noler.com/us/stock/loxo-oncology-inc/available-for-sale-equity-securities-gross-unrealized-gain https://stock.noler.com/us/stock/loxo-oncology-inc/available-for-sale-securities https://stock.noler.com/us/stock/loxo-oncology-inc/capital-expenditures https://stock.noler.com/us/stock/loxo-oncology-inc/capital-units-authorized https://stock.noler.com/us/stock/loxo-oncology-inc/cash-and-cash-equivalents-change https://stock.noler.com/us/stock/loxo-oncology-inc/cash-and-equivalents https://stock.noler.com/us/stock/loxo-oncology-inc/cash-and-restricted-cash https://stock.noler.com/us/stock/loxo-oncology-inc/cash-cash-equivalents-and-short-term-investments https://stock.noler.com/us/stock/loxo-oncology-inc/cash-flow-breakdown https://stock.noler.com/us/stock/loxo-oncology-inc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/loxo-oncology-inc/common-stock-value https://stock.noler.com/us/stock/loxo-oncology-inc/comprehensive-income https://stock.noler.com/us/stock/loxo-oncology-inc/concept-stock-issued-tag-2 https://stock.noler.com/us/stock/loxo-oncology-inc/contract-liability https://stock.noler.com/us/stock/loxo-oncology-inc/contract-with-customer-liability-noncurrent https://stock.noler.com/us/stock/loxo-oncology-inc/conversion-of-stock-shares-issued https://stock.noler.com/us/stock/loxo-oncology-inc/cover-page-shares-outstanding https://stock.noler.com/us/stock/loxo-oncology-inc/current-assets https://stock.noler.com/us/stock/loxo-oncology-inc/current-liabilities https://stock.noler.com/us/stock/loxo-oncology-inc/deferred-finance-costs-noncurrent-net https://stock.noler.com/us/stock/loxo-oncology-inc/deferred-revenue https://stock.noler.com/us/stock/loxo-oncology-inc/deferred-revenue-noncurrent https://stock.noler.com/us/stock/loxo-oncology-inc/deferred-tax-assets-gross https://stock.noler.com/us/stock/loxo-oncology-inc/deferred-tax-assets-in-process-research-and-development https://stock.noler.com/us/stock/loxo-oncology-inc/deferred-tax-assets-net https://stock.noler.com/us/stock/loxo-oncology-inc/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/loxo-oncology-inc/deferred-tax-assets-operating-loss-carryforwards-domestic https://stock.noler.com/us/stock/loxo-oncology-inc/deferred-tax-assets-operating-loss-carryforwards-state-and-local https://stock.noler.com/us/stock/loxo-oncology-inc/deferred-tax-assets-other https://stock.noler.com/us/stock/loxo-oncology-inc/deferred-tax-assets-tax-credit-carryforwards-research https://stock.noler.com/us/stock/loxo-oncology-inc/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals-accrued-liabilities https://stock.noler.com/us/stock/loxo-oncology-inc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/loxo-oncology-inc/deposits-assets-noncurrent https://stock.noler.com/us/stock/loxo-oncology-inc/depreciation https://stock.noler.com/us/stock/loxo-oncology-inc/depreciation-amortization-and-accretion-net https://stock.noler.com/us/stock/loxo-oncology-inc/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/loxo-oncology-inc/effective-tax-rate https://stock.noler.com/us/stock/loxo-oncology-inc/financing-cash-flow https://stock.noler.com/us/stock/loxo-oncology-inc/form-d-other https://stock.noler.com/us/stock/loxo-oncology-inc/general-and-administrative-expense https://stock.noler.com/us/stock/loxo-oncology-inc/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/loxo-oncology-inc/increase-decrease-in-accrued-liabilities https://stock.noler.com/us/stock/loxo-oncology-inc/increase-decrease-in-deferred-revenue https://stock.noler.com/us/stock/loxo-oncology-inc/increase-decrease-in-other-accounts-payable-and-accrued-liabilities https://stock.noler.com/us/stock/loxo-oncology-inc/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/loxo-oncology-inc/increase-decrease-in-prepaid-expense https://stock.noler.com/us/stock/loxo-oncology-inc/increase-decrease-in-security-deposits https://stock.noler.com/us/stock/loxo-oncology-inc/insider-transactions-preferred https://stock.noler.com/us/stock/loxo-oncology-inc/insider-transactions-stock-options https://stock.noler.com/us/stock/loxo-oncology-inc/interest-income-expense-net https://stock.noler.com/us/stock/loxo-oncology-inc/investing-cash-flow https://stock.noler.com/us/stock/loxo-oncology-inc/liabilities-assumed https://stock.noler.com/us/stock/loxo-oncology-inc/long-term-investments https://stock.noler.com/us/stock/loxo-oncology-inc/maturities-of-available-for-sale-securities https://stock.noler.com/us/stock/loxo-oncology-inc/net-cash-from-investing-activities https://stock.noler.com/us/stock/loxo-oncology-inc/net-cash-from-operating-activities https://stock.noler.com/us/stock/loxo-oncology-inc/net-change-in-cash https://stock.noler.com/us/stock/loxo-oncology-inc/net-income https://stock.noler.com/us/stock/loxo-oncology-inc/net-income-loss-available-to-common-stockholders-basic https://stock.noler.com/us/stock/loxo-oncology-inc/number-of-operating-segments https://stock.noler.com/us/stock/loxo-oncology-inc/oci-available-for-sale-adjustment-net-of-tax https://stock.noler.com/us/stock/loxo-oncology-inc/oci-unrealized-holding-gain-loss-on-securities-arising-net-of-tax https://stock.noler.com/us/stock/loxo-oncology-inc/operating-cash-flow https://stock.noler.com/us/stock/loxo-oncology-inc/operating-expenses https://stock.noler.com/us/stock/loxo-oncology-inc/operating-income https://stock.noler.com/us/stock/loxo-oncology-inc/operating-lease-payments-due https://stock.noler.com/us/stock/loxo-oncology-inc/operating-lease-payments-due-current https://stock.noler.com/us/stock/loxo-oncology-inc/operating-lease-payments-due-in-five-years https://stock.noler.com/us/stock/loxo-oncology-inc/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/loxo-oncology-inc/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/loxo-oncology-inc/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/loxo-oncology-inc/operating-lease-payments-due-thereafter https://stock.noler.com/us/stock/loxo-oncology-inc/operating-leases-income-statement-lease-revenue https://stock.noler.com/us/stock/loxo-oncology-inc/operating-leases-rent-expense-net https://stock.noler.com/us/stock/loxo-oncology-inc/other-noncurrent-assets https://stock.noler.com/us/stock/loxo-oncology-inc/other-than-temporary-impairment-losses-investments-portion-in-oci-net-of-tax https://stock.noler.com/us/stock/loxo-oncology-inc/paid-in-capital-increase-in-carrying-amount-of-redeemable-preferred-stock https://stock.noler.com/us/stock/loxo-oncology-inc/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/loxo-oncology-inc/payments-for-fees https://stock.noler.com/us/stock/loxo-oncology-inc/payments-for-proceeds-from-investments https://stock.noler.com/us/stock/loxo-oncology-inc/payments-of-financing-costs https://stock.noler.com/us/stock/loxo-oncology-inc/payments-of-stock-issuance-costs https://stock.noler.com/us/stock/loxo-oncology-inc/payments-to-acquire-available-for-sale-securities https://stock.noler.com/us/stock/loxo-oncology-inc/payments-to-acquire-intangible-assets https://stock.noler.com/us/stock/loxo-oncology-inc/preferred-shares-facts https://stock.noler.com/us/stock/loxo-oncology-inc/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/loxo-oncology-inc/preferred-stock-shares-authorized https://stock.noler.com/us/stock/loxo-oncology-inc/preferred-stock-shares-issued https://stock.noler.com/us/stock/loxo-oncology-inc/preferred-stock-shares-outstanding https://stock.noler.com/us/stock/loxo-oncology-inc/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/loxo-oncology-inc/pretax-income https://stock.noler.com/us/stock/loxo-oncology-inc/prior-period-reclassification-adjustment https://stock.noler.com/us/stock/loxo-oncology-inc/proceeds-from-issuance-initial-public-offering https://stock.noler.com/us/stock/loxo-oncology-inc/proceeds-from-issuance-of-convertible-preferred-stock https://stock.noler.com/us/stock/loxo-oncology-inc/proceeds-from-stock-issued https://stock.noler.com/us/stock/loxo-oncology-inc/proceeds-from-stock-options-exercised https://stock.noler.com/us/stock/loxo-oncology-inc/profit-loss https://stock.noler.com/us/stock/loxo-oncology-inc/property-plant-equipment https://stock.noler.com/us/stock/loxo-oncology-inc/public-float https://stock.noler.com/us/stock/loxo-oncology-inc/reclassifications-of-temporary-to-permanent-equity https://stock.noler.com/us/stock/loxo-oncology-inc/related-party-transaction-due-from-to-related-party-current https://stock.noler.com/us/stock/loxo-oncology-inc/related-party-transaction-expenses-from-transactions-with-related-party https://stock.noler.com/us/stock/loxo-oncology-inc/research-and-development https://stock.noler.com/us/stock/loxo-oncology-inc/restricted-cash-and-cash-equivalents https://stock.noler.com/us/stock/loxo-oncology-inc/retained-earnings https://stock.noler.com/us/stock/loxo-oncology-inc/revenue https://stock.noler.com/us/stock/loxo-oncology-inc/revenue-from-contract-with-customer-excluding-assessed-tax https://stock.noler.com/us/stock/loxo-oncology-inc/shareholders-equity https://stock.noler.com/us/stock/loxo-oncology-inc/shares-authorized https://stock.noler.com/us/stock/loxo-oncology-inc/shares-issued https://stock.noler.com/us/stock/loxo-oncology-inc/shares-issued-price-per-share https://stock.noler.com/us/stock/loxo-oncology-inc/shares-issued-shares-new-issues https://stock.noler.com/us/stock/loxo-oncology-inc/short-term-investments https://stock.noler.com/us/stock/loxo-oncology-inc/stock-based-compensation https://stock.noler.com/us/stock/loxo-oncology-inc/stock-compensation-unrecognized-cost-stock-options https://stock.noler.com/us/stock/loxo-oncology-inc/stock-issued-new-shares-sold https://stock.noler.com/us/stock/loxo-oncology-inc/stock-issued-shares-issued-value-conversion-of-convertible-securities https://stock.noler.com/us/stock/loxo-oncology-inc/stock-issued-shares-issued-value-stock-options-exercised https://stock.noler.com/us/stock/loxo-oncology-inc/stock-split-ratio https://stock.noler.com/us/stock/loxo-oncology-inc/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/loxo-oncology-inc/tax-rate-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/loxo-oncology-inc/tax-rate-reconciliation-nondeductible-expense https://stock.noler.com/us/stock/loxo-oncology-inc/tax-rate-reconciliation-nondeductible-expense-share-based-compensation-cost https://stock.noler.com/us/stock/loxo-oncology-inc/tax-rate-reconciliation-other-reconciling-items-percent https://stock.noler.com/us/stock/loxo-oncology-inc/tax-rate-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/loxo-oncology-inc/tax-rate-reconciliation-tax-credits-research https://stock.noler.com/us/stock/loxo-oncology-inc/temporary-equity-accretion-to-redemption-value https://stock.noler.com/us/stock/loxo-oncology-inc/temporary-equity-accretion-to-redemption-value-adjustment https://stock.noler.com/us/stock/loxo-oncology-inc/temporary-equity-carrying-amount-attributable-to-parent https://stock.noler.com/us/stock/loxo-oncology-inc/temporary-equity-par-or-stated-value-per-share https://stock.noler.com/us/stock/loxo-oncology-inc/temporary-equity-shares-authorized https://stock.noler.com/us/stock/loxo-oncology-inc/total-assets https://stock.noler.com/us/stock/loxo-oncology-inc/total-liabilities https://stock.noler.com/us/stock/loxo-oncology-inc/total-liabilities-and-equity https://stock.noler.com/us/stock/loxo-oncology-inc/unrecognized-tax-benefits https://stock.noler.com/us/stock/loxo-oncology-inc/utb-increase-from-current-year-positions https://stock.noler.com/us/stock/loxo-oncology-inc/utb-increase-from-prior-year-positions https://stock.noler.com/us/stock/loxo-oncology-inc/valuation-allowance-deferred-tax-asset-change-in-amount https://stock.noler.com/us/stock/loxo-oncology-inc/weighted-average-number-of-share-outstanding-basic-and-diluted